Clinical Trial Update: Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

AAVantgarde Bio Srl is conducting a Phase 1/2 trial of subretinally injected AAVB-081 for Usher syndrome type 1B with retinitis pigmentosa; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa
• Usher Syndrome Type 1b

Drugs mentioned

• AAVB-081

Snippet

Sponsor: AAVantgarde Bio Srl | Conditions: Usher Syndrome, Type 1B | Phase 1, Phase 2 | Status: RECRUITING